Clinical trial
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
NCT01217957 is registered in ClinicalTrials.gov with Millennium Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- November 22, 2010
- Completion date
- February 2, 2018
- Enrollment
- 65 (actual)
- Sites
- 16
Conditions
As the registry lists them; a condition with its own page is linked.